Leqvio vs Lipitor
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Leqvio | US Lipitor | |
|---|---|---|
| Generic name | inclisiran | atorvastatin |
| Drug class | siRNA PCSK9-Lowering Therapy | Statin |
| Treats | High cholesterol, cardiovascular disease | High cholesterol, cardiovascular prevention |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Novartis | Pfizer |
| Year approved | 2021 | 1996 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $90M | $60M |
| Common side effects | Injection site reactions, Joint pain, Urinary tract infection, Shortness of breath | Muscle pain or weakness, Liver problems, Increased blood sugar, Memory problems |
Frequently asked questions
Is Leqvio or Lipitor better?
Neither is universally "better." Leqvio (inclisiran) and Lipitor (atorvastatin) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Leqvio and Lipitor?
Leqvio is a siRNA PCSK9-Lowering Therapy made by Novartis, while Lipitor is a Statin made by Pfizer. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Leqvio has the larger estimated TV advertising budget of the two.